PABPC3

Across TCGA pan-cancer cohorts, PABPC3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PABPC3 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PABPC3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PABPC3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where PABPC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.673	1.000	.003	35	view →
PDAC	OS	Tertile	All	0.401	0.860	.018	13	view →
HNSC	DFS	Median	All	0.509	0.829	.010	10	view →
LSCC	OS	Median	All	0.979	0.710	<.001	8	view →
COAD	DFS	Quartile	All	0.553	1.000	.045	6	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.154	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PABPC3–CCRCC (DFS)

Open the CCRCC breakdown →